US Physical Therapy Q2 Results: EPS misses estimate despite sales beat
US Physical Therapy’s Q2 results show a mixed bag for investors. Adjusted EPS of $0.75 missed the $0.84 consensus by 10.71% and fell 7.41% YoY from $0.81. Conversely, sales of $214.059 million exceeded the $211.307 million estimate by 1.30%, driven by an 8.47% YoY increase from $197.344 million.

*this image is generated using AI for illustrative purposes only.
US Physical Therapy (NYSE: USPH) reported second-quarter adjusted earnings per share of $0.75, missing the analyst consensus estimate of $0.84 by 10.71 percent. The result marks a 7.41 percent decrease from the $0.81 per share recorded in the same period last year. While profitability metrics fell short of market expectations, the company demonstrated top-line strength, with quarterly sales reaching $214.059 million. This figure beat the analyst consensus estimate of $211.307 million by 1.30 percent and represented an 8.47 percent increase over the $197.344 million reported in the prior-year quarter.
Financial Performance Overview
The divergence between revenue growth and earnings performance highlights a pressure point in the company’s margin structure during the quarter. While sales expanded significantly, the adjusted EPS declined both sequentially against estimates and annually against prior results.
| Metric | Q2 Current | Q2 Prior Year | YoY Change | Analyst Estimate | vs Estimate |
|---|---|---|---|---|---|
| Adjusted EPS | $0.75 | $0.81 | -7.41% | $0.84 | -10.71% |
| Sales | $214.059M | $197.344M | +8.47% | $211.307M | +1.30% |
What the Numbers Show
The data reveals a clear disconnect between operational volume growth and bottom-line profitability. Revenue grew by 8.47 percent year-over-year, indicating successful patient acquisition or service utilization expansion. However, this growth did not translate into proportional earnings gains; instead, adjusted EPS fell by 7.41 percent. This suggests that cost structures or non-operating expenses may have increased at a faster rate than revenue, eroding margins despite the sales beat. Investors should monitor whether this margin compression is a temporary anomaly or a structural shift in the company’s cost base.
What specific cost drivers contributed to the margin compression despite the 8.47% revenue growth?
Will management implement immediate cost-cutting measures or operational efficiencies to restore EPS to consensus levels in Q3?
How does this divergence between top-line strength and bottom-line weakness impact USPH's valuation multiples compared to healthcare sector peers?



























